Medicare Copay ‘Smoothing’ Plan Shows Nothing Is Simple In Part D
Guidance on how to implement a new policy to permit Part D beneficiaries to pay high copays in monthly installments (rather than all at once at the pharmacy counter) shows that there is no such thing as a straight-forward change in the drug benefit program.
You may also be interested in...
The other seven drugs on the initial list for negotiation are already heavily rebated and CMS could choose not to go much lower than current net prices, SSR Health report points out.
However, Part D drugs subject to government price setting under the Inflation Reduction Act will still face pharmacy benefit manager demands for additional rebates in return for preferential formulary status.
With enactment of the drug pricing reform provisions in the Inflation Reduction Act, stakeholders now turn their attention to the implementing regulations that will be developed by the Centers for Medicare and Medicaid Services.